225Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy in complement to 177Lu-radiotherapy. 225Ac-DOTAZOL is a potent bisphosphonate for alpharadiotherapy of bone diseases tested in prostate cancer patients.

The first preclinical data were published in 2018. 225Ac-DOTAZOL confirms the well-known pharmacology of DOTAZOL derivatives (68Ga and 177Lu) in preclinical evaluations.

Target/Mechanism: Bones

Carrier/Ligand: n/a

Radiation Type: alpha particle (α)